Teva Pharmaceutical Industries (TEVA) Current Assets (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Current Assets for 18 consecutive years, with $13.7 billion the latest figure, recorded in Q1 2026.

• Quarterly Current Assets rose 18.93% year-over-year to $13.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.7 billion (up 18.93% YoY) and the FY2025 annual result came in at $13.9 billion, up 11.11% from the prior year.
• Current Assets declined to $13.7 billion in Q1 2026 per TEVA's latest filing, from $13.9 billion in the prior quarter.
• Over the last five years, Current Assets for TEVA reached as high as $13.9 billion in Q4 2025 and fell as low as $11.4 billion in Q3 2023.
• A 5-year average of $12.3 billion and a median of $12.3 billion in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2023 — Current Assets dropped 7.63% — and 2026, when it rose 18.93%.
• Year by year, Current Assets stood at $12.1 billion in 2022, then climbed by 3.6% to $12.5 billion in 2023, then grew by 0.54% to $12.6 billion in 2024, then climbed by 11.11% to $13.9 billion in 2025, then declined by 1.69% to $13.7 billion in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $13.7 billion, $13.9 billion, and $12.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.